Rifapentine access in Europe: growing concerns over key tuberculosis treatment component - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue European Respiratory Journal Année : 2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Résumé

Rifapentine, a synthetic derivate of rifampicin which was developed in 1965, has interesting pharmacological properties, including a long terminal half-life (13 h, compared to 2-3 h for rifampicin) and promising bactericidal activity against Mycobacterium tuberculosis. Despite being approved in 1998 by the US Food and Drug Administration (FDA) for the treatment of pulmonary tuberculosis, its global use has been limited by unavailability. In the past decade, new evidence has emerged to define rifapentine as a key component for treatment of active disease and latent infection with M. tuberculosis (LTBI).
Fichier principal
Vignette du fichier
ERJ Rpt 2022.pdf (619.75 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03689715 , version 1 (07-06-2022)

Identifiants

Citer

Lorenzo Guglielmetti, Gunar Günther, Claude Leu, Daniela Cirillo, Raquel Duarte, et al.. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal, 2022, 59 (5), pp.2200388. ⟨10.1183/13993003.00388-2022⟩. ⟨hal-03689715⟩
20 Consultations
63 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More